Abstract Number: 1107 • 2019 ACR/ARP Annual Meeting
Are Rheumatologists Correctly Identifying and Controlling Traditional Cardiovascular Risk Factors?
Background/Purpose: Chronic systemic inflammation generated by rheumatic diseases (RD) is related to the increased cardiovascular risk (CVR) in this population. However, the coexistence of traditional…Abstract Number: 1592 • 2019 ACR/ARP Annual Meeting
Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in SLE patients. Hypocomplementemia, antiphospholipid antibodies, and elevated antibodies to RNP and Ro are…Abstract Number: 2059 • 2019 ACR/ARP Annual Meeting
Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases
Background/Purpose: Subjects with rheumatic diseases have an increased risk of cardiovascular (CV) morbimortality. Hypertension (HTN) is a key modifiable risk factor for CV events. A…Abstract Number: 2828 • 2019 ACR/ARP Annual Meeting
Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams
Background/Purpose: Despite recognition that rheumatoid arthritis (RA) accelerates cardiovascular disease (CVD) and hypertension impacts 50% of RA patients, up to 50% lack blood pressure (BP)…Abstract Number: 338 • 2019 ACR/ARP Annual Meeting
Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults
Background/Purpose: The association between serum urate and hypertension continues to be a matter of controversy. Studies in adolescents provided evidence for the efficacy of urate…Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…Abstract Number: 301 • 2018 ACR/ARHP Annual Meeting
Rheumatology Clinic Staff Needs for Partnering to Improve Blood Pressure and Tobacco Risk Management
Background/Purpose: Patients with rheumatologic conditions are at a higher risk of cardiovascular disease (CVD) than peers. High blood pressure (BP) and tobacco use exacerbate CVD…Abstract Number: 514 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better?
Background/Purpose: The increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA) has been well established. While the reasons for an increased risk of CVD…Abstract Number: 722 • 2018 ACR/ARHP Annual Meeting
Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased mortality compared to the general population. As outcomes related to disease control have improved, this mortality…Abstract Number: 2243 • 2018 ACR/ARHP Annual Meeting
Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults
Background/Purpose: Serum urate (sUA) has been associated with blood pressure in most but not all studies. This study aims to test whether there are sex…Abstract Number: 2662 • 2018 ACR/ARHP Annual Meeting
Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials
Background/Purpose: Hypertension predicts poor long-term renal outcomes for patients with lupus nephritis (LN) [1, 2]. We sought to characterize relationships between blood pressure and proteinuria…Abstract Number: 670 • 2017 ACR/ARHP Annual Meeting
Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment
Background/Purpose: LN is characterized by deposition of immune complexes in the kidney. Activation of the classical complement pathway by dsDNA is believed to play a…Abstract Number: 1088 • 2017 ACR/ARHP Annual Meeting
Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure
Background/Purpose: The Centers for Disease Control and Prevention director has said “nothing will save more lives” than protocols to control blood pressure (BP). BP is…Abstract Number: 1267 • 2017 ACR/ARHP Annual Meeting
Blood Pressure Control over Time in Childhood-Onset Systemic Lupus Erythematous
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of increased long-term morbidity and mortality in systemic lupus erythematosus (SLE). As an important modifiable risk factor…Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…
- 1
- 2
- 3
- 4
- Next Page »